{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:05:16Z","timestamp":1778659516654,"version":"3.51.4"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,3,15]]},"DOI":"10.18632\/aging.202573","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T06:01:30Z","timestamp":1614319290000},"page":"7147-7165","source":"Crossref","is-referenced-by-count":10,"title":["No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis"],"prefix":"10.18632","volume":"13","author":[{"given":"Jie","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Surgery, Maternal and Child Health Hospital of Yongchuan, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Fifth People\u2019s Hospital of Chengdu, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa-Bao","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Qingdao Women and Children\u2019s Hospital, Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Qin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Children Healthcare, Maternal and Child Health Hospital of Yongchuan, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Chao","family":"Zhong","sequence":"additional","affiliation":[{"name":"Graduate School, Chongqing Medical University, Chongqing, China"},{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"29","author":"Iloeje","year":"2006","journal-title":"JAMA"},{"key":"3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"13","author":"Chen","year":"2006","journal-title":"Gastroenterology"},{"key":"4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"6","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"6","author":"Wong","year":"2018","journal-title":"Hepatology"},{"key":"6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"1","author":"Hou","year":"2016","journal-title":"Hepatol Int"},{"key":"7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.","volume":"5","author":"Wong","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jvh.13237","article-title":"A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance.","volume":"2","author":"Yuen","year":"2020","journal-title":"J Viral Hepat"},{"key":"9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in caucasians with chronic hepatitis B.","volume":"6","author":"Kesk\u0131n","year":"2017","journal-title":"Hepatology"},{"key":"10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.","volume":"6","author":"Jang","year":"2020","journal-title":"Gut"},{"key":"11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs. Tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea.","volume":"7","author":"Um","year":"2019","journal-title":"J Hepatol"},{"key":"12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B.","volume":"11","author":"Yasuda","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir.","volume":"2","author":"Shin","year":"2018","journal-title":"J Viral Hepat"},{"key":"14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.","volume":"15","author":"Wong","year":"2020","journal-title":"Gastroenterology"},{"key":"15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.","volume":"5","author":"Lim","year":"2019","journal-title":"JAMA Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jgh.15031","article-title":"Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis.","volume":"3","author":"Kim","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"17","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir.","volume":"1","author":"Cho","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in caucasian patients with chronic hepatitis B.","volume":"7","author":"Veelken","year":"2020","journal-title":"J Hepatol"},{"key":"19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/gutjnl-2019-319867","article-title":"No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.","volume":"7","author":"Ioannou","year":"2021","journal-title":"Gut"},{"key":"20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis.","volume":"9","author":"Yu","year":"2020","journal-title":"Liver Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","article-title":"Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.","volume":"6","author":"Zhong","year":"2020","journal-title":"Gut"},{"key":"22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.","volume":"1","author":"Huang","year":"2019","journal-title":"BMC Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis.","volume":"2","author":"Lim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31267","article-title":"Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"25","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.","volume":"3","author":"Yu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.","volume":"1","author":"Jia","year":"2020","journal-title":"Hepatol Int"},{"key":"27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/apt.15603","article-title":"Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?","volume":"5","author":"Li","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"28","doi-asserted-by":"publisher","first-page":"e00236","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis.","volume":"1","author":"Lai","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.","volume":"1","author":"Yan","year":"2020","journal-title":"Gut Liver"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir.","author":"Park","year":"2020","journal-title":"Dig Dis Sci"},{"key":"32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/apt.16116","article-title":"Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-na\u00efve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.","volume":"5","author":"Chien","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"33","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-020-70433-z","article-title":"Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.","volume":"1","author":"Hwang","year":"2020","journal-title":"Sci Rep"},{"key":"34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jfma.2016.08.006","article-title":"Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.","volume":"11","author":"Hung","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/bjc.2012.193","article-title":"Risk of liver cancer among US male veterans with cirrhosis, 1969-1996.","volume":"10","author":"McGlynn","year":"2012","journal-title":"Br J Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"38","author":"Subramanian","year":"2013","journal-title":"Lancet"},{"key":"37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/apt.15020","article-title":"Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.","volume":"4","author":"Kim","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"38","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.","volume":"4","author":"Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects.","volume":"6","author":"Chan","year":"2015","journal-title":"Hepatology"},{"key":"40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.fertnstert.2012.05.035","article-title":"Is early age at menarche a risk factor for endometriosis? a systematic review and meta-analysis of case-control studies.","volume":"9","author":"Zondervan","year":"2012","journal-title":"Fertil Steril"},{"key":"41","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"28","author":"Thacker","year":"2000","journal-title":"JAMA"},{"key":"42","unstructured":"Wells, Shea, O\u2019Connell, Peterson, Welch, Losos, Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"43","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias.","volume":"5","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"31","author":"Minder","year":"1997","journal-title":"BMJ"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T16:22:42Z","timestamp":1617726162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,15]]}},"alternative-id":["202573","33658397"],"URL":"https:\/\/doi.org\/10.18632\/aging.202573","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}